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INTRODUCTION
Idiopathic pulmonary fibrosis (IPF)/usual inter-
stitial pneumonia (UIP) is a progressive and lethal
lung disease characterized by the proliferation of
fibroblasts and deposition of extracellular matrix
(ECM) including fibrillar collagens, fibronectin, elas-
tic fibers and proteoglycans (1, 2). While corticoster-
oids and other immunosuppressants have been
used for the treatment of patients with IPF, the
response rate to these agents was low, and the five-
year survival rate of IPF is less than 50% (3, 4). Re-
cent guidelines for IPF describe that no effective
pharmacological therapy has been developed so far
(5). For this reason, novel therapeutic modalities
are still of strong interest.
However, the molecular pathogenesis involved in
pulmonary fibrosis is not fully investigated. In ad-
dition, from the therapeutic point of view, we do not
have the right answer to the question which is best
target to treat pulmonary fibrosis.
More recently, Nintedanib (BIBF1120) which is
the multikinase inhibitor of three receptors for plate-
let-derived growth factor (PDGF), fibroblast growth
factor (FGF) and vascular endothelial growth factor
(VEGF) have been shown the inhibitory activity for
the progression of IPF in TOMORROW phase II
clinical trial (6). Based on this trial, PDGF is be-
lieved to be one of promising targets for therapy of
IPF. In this review, we consider the update molecu-
lar pathogenesis in IPF, and discuss the possibility
of targeting PDGF as a therapeutic approach of IPF.
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MOLECULAR PATHOGENESIS IN IPF
The molecular mechanisms involved in the pro-
gression of IPF are still not fully understood, whereas
the alveolar epithelial type II cells (AECII) and fi-
broblasts are thought to be main players (Figure 1).
As the first event, AECII injury is caused by endo-
plasmic reticulum (ER) stress, lysosomal stress, and
mitochondrial and DNA damage (7, 8). AECII are
known to have genetic predisposition like gene mu-
tations of surfactant protein C or A2, telomerase and
MUC5B in subjects with familial pulmonary fibrosis,
which lead to be susceptible for the second stimuli
such as cigarette smoking or viral infection. After
the second stimuli, the injured AECs have the ten-
dency to be apoptotic. The link of injured AECII and
fibrosis is not fully understood, but it was reported
that those cells could produce the fibrotic mediators.
Among profibrotic mediators, transforming growth
factor (TGF)-β and PDGF are thought to play a
critical role in the fibrogenesis of the lungs.
PDGF AND PDGF RECEPTORS
PDGF is a homo- or heterodimeric molecule with
a molecular weight of 30 kDa (7). PDGF genes are
consisted of four different genes including PDGF-
A, -B, -C and -D, which are located on chromo-
somes 7, 22, 4 and 11, respectively (9, 10). There
are two types of PDGF receptors (PDGFRs), α and
β, which have a molecular weight of 170-180 kDa,
and composed of homo- or heterodimers. The pos-
sible PDGF-PDGFR interactions are multiple and
complex in in vitro study as shown in figure 2 (11).
However, the in vivo study showed the binding of
PDGF-AA or -CC to PDGFR-α, and PDGF-BB to
PDGFR-β (11). PDGF dimers can bind their recep-
tors and induce the dimerization of PDGFR, which
allow their autophosphorylation of tyrosine residues
in trans between two receptors (9). After the auto-
phosphorylation, activated PDGFR can coupled with
various signal transduction molecules such as Ras-
MAPK through Grb2 and Shc adaptor proteins, and
phosphatidyl inositol-3 kinase and phospholipase
C-γ. PDGFR interacts with integrins and induced
cell migration through activation focal adhesion
kinase (FAK).
Figure 1 Molecular pathogensis of IPF
Alveolar epithelia cells (AECs) are known to have genetic predisposition like gene mutations of surfactant protein C or A2, telomerase
and MUC5B in subjects with familial pulmonary fibrosis, which induce endoplasmic reticulum (ER) stress and lead to be suscepti-
ble for the second stimuli such as cigarette smoking or viral infection. After the second stimuli, the injured AECs have the tendency
to be apoptotic and produce the profibrotic mediators. Although the link of injured AECs and fibrosis is not fully understood, among
profibrotic mediators, transforming growth factor (TGF)-β and PDGF are thought to play a critical role in the fibrogenesis of the lungs,
which induce the proliferation and differentiation to myofibroblasts of fibroblasts.
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EXPRESSION OF PDGFS AND PDGFRS
PDGFs are expressed in many types of cells in-
cluding fibroblasts, vascular endothelial cells, macro-
phages as well as platelets/megakaryocytes (9). It is
known that the expression of PDGFs is up-regu-
lated by various inflammatory cytokines and growth
factors including TGF-β and PDGF themselves.
PDGFRs are also expressed in various cells al-
though the classical targets of PDGF are fibro-
blasts and smooth muscle cells. The expression of
PDGFRs is also induced by various stimuli. In con-
trast to PDGFs, expression of PDGFR in some cells
is limited to PDGFR-α or PDGFR-β, but not both.
BIOLOGICAL ACTIVITIES THROUGH PDGF/
PDGFR
PDGF is known to be a major mitogen for
mesenchymal cells. PDGF is a strongest stimulus of
proliferation of fibroblasts (9). In addition, binding
of PDGF to their receptors induces Ca2+ influx and
rearrangement of the cytoskeleton involving changes
in the arrangement of actin stress fibers. In terms of
these responses, PDGF also stimulates the migration
of various cells.
LUNG DEVELOPMENT AND PDGFS/
PDGFRS
The knock-out mice of the PDGF-A gene showed
the homozygous lethal with two different restric-
tion points, one prenatally and one postnatally (12).
Postnatally surviving PDGF-A-deficient mice de-
velop lung emphysema secondary due to the loss
of alveolar myofibroblasts which has PDGFR-α. On
the other hand, the PDGFR-α null mice showed the
cranial malformations and deficiency of myotome
formation (13). Mice deficient for PDGF-B revealed
renal, cardiovascular and hematological abnormali-
ties (14). Similarly, PDGFR-βmutant mice exhib-
ited abnormal kidney development and hematologi-
cal disorders, but cardiovascular abnormality was
not detected (15). In summary, PDGF-A/PDGFR-α
pathway plays a role in the secondary septation
process, since PDGFR-α -expressing cells locate
in the alveolar entry ring and have characteristics of
myofibroblasts (16).
PDGF AND PULMONARY FIBROSIS
It is known that PDGF is one of the growth factors
which play a role in the pathogenesis of pulmonary
fibrosis (9, 11). In the animal models, bleomycin-
induced pulmonary fibrosis has been used for the
analysis of molecular pathogenesis in mice or rats.
Figure 2 PDGF-PDGFR system
The four PDGF proteins make a homo- or hetero-dimers and bind to PDGF receptors. The black bold arrow indicates the bindings
which are confirmed in vivo . The blue arrows indicate the binding in cell culture. The hatched arrows indicate weak interactions or
conflicting results.
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Maeda et al. reported that expression of the PDGF-
A gene increased in bleomycin-induced pulmo-
nary fibrosis models in mice using semi-quantita-
tive reverse transcriptase-polymerase chain reac-
tion (RT-PCR)(17). Walsh et al. have examined the
bronchoalveolar lavage fluid of rats treated with a
bleomycin, and could find the 38-40 kDa and 29
kDa peptides, which were detected with anti-PDGF-
BB and anti-PDGF-AA antibodies, respectively,
showed the growth-promoting activity of lung fibro-
blasts (18). The growth-promoting activity was neu-
tralized 64% by anti-PDGF-BB antibody and 15%
by anti-PDGF-AA antibody. In contrast, Zhuo et al.
showed that PDGF-C gene, but not PDGF-A, B and
D, was induced in the lungs of mice treated with
bleomycin by Northern blot analysis (19). Shimizu
et al. reported that both PDGF-A and -B was in-
duced and elevated in bleomycin-treated lungs of
mice at the levels of both mRNA and protein (20).
Adoptive transfer of an adenovirus expressing the
PDGF-B gene into the lung induced severe fibrosis
in mice (21). From these reports, the expression of
PDGF isoforms could be enhanced in fibrogenesis
of the lungs, but the details are required to be fur-
ther analyzed.
On the other hand, enhanced expression of PDGF
in the epithelial cells and alveolar macrophages in
lungs of patients with IPF has been reported (22,
23). However, the mechanisms involved in the en-
hanced expression and action of PDGF in the fibrotic
lung are poorly understood. Recently, Gochuico et
al. has examined the growth factors in alveolar lin-
ing fluids of patients with rheumatoid arthritis com-
plicated with pulmonary fibrosis, and reported that
PDGF-AB and -BB, but not TGF-β and PDGF-AA,
was associated with the progressive stage of pul-
monary fibrosis (24), indicating the importance of
PDGF-B in the fibrogenesis of the lungs.
ANTIFIBROTIC EFFECTS OF TARGETING
PDGF/PDGFR SIGNALING PATHWAY IN
ANIMAL MODELS
Several evidences described above suggest the
targeting PDGF/PDGFR signaling pathway might
lead to show the therapeutic effects against pulmo-
nary fibrosis. This hypothesis has been investigated
using animal models of pulmonary fibrosis with
specific inhibitors for PDGFR.
Rice et al. firstly reported that AG1296, the inhibi-
tor for the tyrosine kinase of PDGFR, prevented
pulmonary fibrosis induced by vanadium pentoxide
(V2O5) in rats (25). Since AG1296 is a compound
which has been used for in vitro experiments, mo-
lecular targeted drugs which have been developed
for treatment of patients with malignancy should be
investigated their antifibrotic effects. Among them,
imatinib mesylate (previously called STI571, Gleevec
in the United States and Glivec in Europe) is a po-
tent and specific tyrosine kinase inhibitor against c-
abl, bcr-abl and c-kit. Imatinib has been demon-
strated to be highly active in chronic myeloid leu-
kemia (CML) and gastrointestinal stromal tumors
(GIST) (26-29). The reported data regarding the
specificity of imatinib for various tyrosine kinases
shows that imatinib also specifically inhibits PDGFR
tyrosine kinase (30). Therefore, we and others have
tried to demonstrate antifibrotic effects of imatinib
in various pulmonary fibrosis models. As shown in
figure 3, imatinib strongly inhibited the fibrogenesis
in the lungs treated with bleomycin via inhibiting the
growth of mesenchymal cells in vivo in mice (31).
Daniels et al. reported that imatinib could inhibit
the activity of TGF-β via inhibiting c-Abl kinase in
addition to the blocking of PDGFR signaling (32).
They also demonstrated that imatinib prevented
bleomycin-induced pulmonary fibrosis in mice. Fur-
thermore, Abdollahi et al. demonstrated the antifi-
brotic effects of imatinib in murine radiation-induced
lung fibrosis (33). In their experiments, they used
three kinds of small molecule inhibitors, imatinib,
SU9518 and SU11657, which can inhibit the com-
mon receptor PDGFR. Therefore antifibrotic effects
of three inhibitors were strongly suggested to be
mediated by blocking PDGFR. In addition, Yoshida
et al. reported that the in vivo gene transfer of an
extracellular domain of PDGFR-β reduced bleomy-
cin-induced pulmonary fibrosis (34). These results
suggested that PDGFR is one of therapeutic target
for pulmonary fibrosis.
Imatinib has also been reported to prevent fibro-
genesis in the liver and kidneys (35-38). These re-
sults in addition to inhibitory effects of myelofibrosis
(39, 40) suggest that imatinib might serve as an anti-
fibrotic drug for various fibrotic diseases in humans.
Recently, the antifibrotic effects of other inhibi-
tors, which could show higher activity compared
to imatinib, have been reported. For example,
BIBF1000 which inhibited PDGFR, VEGFR and
FGFR was reported to reduce pulmonary fibrosis
induced by a bleomycin in rats (41). Nilotinib was
also reported to show higher antifibrotic activity as
compared to imatinib (42).
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ANTIFIBROTIC EFFECTS OF TARGETING
PDGF/PDGFR SIGNALING PATHWAY IN
HUMAN
Based on the preclinical studies, the application
of imainib for treatment of patients with pulmonary
fibrosis has been expected.
In the earlier experiences in clinical use of imatinib,
several case reports showed the favorable activity
of imatinib in patients with connective tissue dis-
eases including systemic sclerosis (SSc) or mixed
connective tissue disease (MCTD) (43-45). Chung
et al. reported two cases with SSc treated with
imatinib. Both patients showed the improvement
of skin tightening after the use of 200 mg/day of
imatinib for three months (43). In addition, a forced
vital capacity (FVC) in one patient who has lung
involvement of SSc was improved from 48% of pre-
dicted to 52%. Sfikakis et al. reported the severe case
of SSc who have treated with 400 mg/day imatinib
for six months (44). This patient showed the im-
provement of FVC from 68.0% to 88.3% predicted.
Distler et al. also reported the improvement of pul-
monary function and HRCT findings in patients with
MCTD (45). The recent phase IIa, single-arm, open-
label clinical trial with imatinib against SSc showed
the efficacy in modified Rodnan skin score and FVC
(46), whereas the increased adverse events were
observed, and some trials were prematurely termi-
nated for safety reasons (47).
On the other hand, the clinical trial of IPF with
single dose of imatinib has been conducted and
performed in USA (48). Although serious adverse
events were not more common in the imatinib group,
treatment with imatinib did not affect lung func-
tion such as FVC and the diffusing capacity of the
lung (DLco) as well as survival of IPF patients. How-
ever, this trial has several problems in the design
and results which was pointed out in the discussion
of this paper and the editorial by Thannickal VJ and
Roman J (49). First, this study was conducted by
the anticipation of 50% incidence of achieving the
primary endpoint of disease progression or death
over 96 weeks of treatment, whereas the incidence
in placebo group was 31.6%, indicating the under-
power of this study to detect the differences between
groups. Second, theoretically, PDGFR are expressed
not only in fibroblasts, but also in epithelial or other
cells. To inhibit PDGFR signaling pathway can
block the proliferation and migration of fibroblasts,
but the blocking of PDGFR may affect the function
of epithelial cells to prevent the fibrogenesis. In fact,
Vuorinen et al. reported that PDGFR-β are preferen-
tially expressed in lung parenchyma, but PDGFR-α
are strongly expressed in epithelium in addition to
lung parenchyma in the lungs of IPF patient (50).
Figure 3 Antifibrotic effects of imatinib in pulmonary fibrosis induced by bleomycin in mice. Treatment with imatinib inhibited
puolmonary fibrosis induced by bleomycin in a dose-dependent manner (A). The BrdU staining showed the reduced number of
proliferating cells in inter -alveolar space (B). Adapted from reference 31.
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Third, the pharmacological consideration of imatinib
was also pointed out. We reported the resistance
mechanism of imatinib mediated by α1-acid gly-
coprotein (AGP), which can bind to imatinib and
block the effects of imatinib (51). AGP was elevated
in serum of both bleomycin-treated mice and pati-
ents with IPF. Therefore, the patients enrolled in
clinical trial might be better to be selected by the
level of AGP. The more extensive and fine preclini-
cal study could be required to focus the molecular
target for therapeutic approach of IPF.
However, the growth factors are still in central
mediators to promote pulmonary fibrosis. Recently,
promising clinical trials targeting the signaling
of growth factors have been reported. BIBF1120,
which is derivative of BIBF1000, was reported to
inhibit the progression and acute exacerbation of
IPF in phase II TOMORROW study (6).
FUTURE PERSPECTIVES
The international phase III clinical trial using
BIBF1120 for IPF has been in progress. BIBF1120
can inhibit VEGFR and FGFR in addition to PDGFR.
The role of VEGFR and FGFR in the progression
of pulmonary fibrosis is still unclear. Therefore,
PDGFR still play a central role as a therapeutic
target in the progression of IPF. The establishment
of molecular targeting therapy against growth fac-
tors including PDGF would be expected in clinic.
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